AstraZeneca Overview

  • Status
  • Public
  • Employees
  • 70,600
Employees
  • Stock Symbol
  • AZN
Stock Symbol
  • Investments
  • 66
  • Share Price
  • $106.52
  • (As of Wednesday Closing)

AstraZeneca General Information

Description

A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The company sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.

Contact Information

Formerly Known As
Zeneca Group
Ownership Status
Publicly Held
Financing Status
Formerly PE-Backed
Primary Industry
Pharmaceuticals
Stock Exchange
LON
Primary Office
  • 1 Francis Crick Avenue
  • Cambridge Biomedical Campus
  • Cambridge CB2 0AA
  • England, United Kingdom
+44 020 0000 0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

AstraZeneca Stock Performance

(As of Wednesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$106.52 $104.01 $72.78 - $127.21 $136B 1.31B 2.09M $1.90

AstraZeneca Financials Summary

In Thousands,
USD
TTM 30-Sep-2020 FY 2019 31-Dec-2019 FY 2018 31-Dec-2018 FY 2017 31-Dec-2017
EV 157,814,810 145,733,740 112,692,471 101,489,615
Revenue 25,871,000 24,384,000 22,090,000 22,465,000
EBITDA 7,011,000 5,380,000 6,006,000 5,941,000
Net Income 2,497,000 1,335,000 2,155,000 3,001,000
Total Assets 64,112,000 61,377,000 60,651,000 63,354,000
Total Debt 22,339,000 18,227,000 19,113,000 17,807,000
Public Fundamental Data provided by Morningstar, Inc. disclaimer

AstraZeneca Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore AstraZeneca‘s full profile, request access.

Request a free trial

AstraZeneca Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The company sells br
Pharmaceuticals
Cambridge, United Kingdom
70,600 As of 2019
000
00000000 000

00000000

e dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur s
000000000000000
Brentford, United Kingdom
00000 As of 0000
00000000000

0000000

didunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco
0000000000000
Gaithersburg, MD
000 As of 0000
00000
000000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

AstraZeneca Competitors (49)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
GlaxoSmithKline Corporation Brentford, United Kingdom 00000 00000000000
0000000 Corporation Gaithersburg, MD 000 00000 000000000 00000
000000 00000000000 Corporation Montreal, Canada 000 00000 00000000 00000
00000000 Corporation Richmond, VA 000 00000 0000 00000
00000 Corporation Tokyo, Japan 00000 0000
You’re viewing 5 of 49 competitors. Get the full list »

AstraZeneca Executive Team (79)

Name Title Board Seat Contact Info
Pascal Soriot Chief Executive Officer, Board Member & Executive Director
Marc Dunoyer Executive Director & Chief Financial Officer
Katarina Ageborg Executive Vice-President, Sustainability and Chief Compliance Officer; President AstraZeneca AB, Sweden
Robert Busch Controller
Michele Meixell Director, US Corporate External Communication & Senior Director, External and Executive Communication
You’re viewing 5 of 79 executive team members. Get the full list »

AstraZeneca Board Members (19)

Name Representing Role Since
00000 00000000 Self Board Member 000 0000
000000000 000000 Self Board Member 000 0000
000000 000000000 Self Board Member 000 0000
0000 000000000 Self Non-Executive Chairman of the Board, Chairman of the Nomination and Governance Committee & Member of the Remuneration Committee 000 0000
0000 0000000 AstraZeneca Executive Director & Chief Financial Officer 000 0000
You’re viewing 5 of 19 board members. Get the full list »

AstraZeneca Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

AstraZeneca Investments & Acquisitions (66)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
00000 000000000000 17-Sep-2020 000000000 00000 00 Buildings and Property 0000000 00000000 00.0
0000000 11-Sep-2020 00000 00000 00 00.000 Other Devices and Supplies
000000000 (0000000 27-Jan-2020 000000000 00000 00 Buildings and Property 0000000 00000000 00.0
0000000 000000 000 30-Sep-2019 000000000 00000 00 0000 Buildings and Property
ADC Therapeutics 12-Jun-2019 Later Stage VC 00000 Drug Discovery
You’re viewing 5 of 66 investments and acquisitions. Get the full list »

AstraZeneca Subsidiaries (11)

Company Name Industry Location Founded
Acerta Pharma Drug Discovery Oss, Netherlands 2012
00 000000 Drug Discovery Coppell, TX 0000
00000 000000000000 Therapeutic Devices Redwood City, CA 0000
0000000 000000 Pharmaceuticals Tokyo, Japan 0000
0000 00000000 Biotechnology Waltham, MA 0000
You’re viewing 5 of 11 subsidiaries. Get the full list »

AstraZeneca Exits (13)

Company Name Exit Date Exit Type Exit Size Status Buyers
00000000 000000000 25-Apr-2018 00000 00000 00 0000 Completed
  • 10 buyers
00000 000 13-Mar-2018 00000 00000 00 00000 Completed
  • 5 buyers
0000000 0000000000 07-Sep-2016 00000 00000 00 00000 Completed
  • 2 buyers
00000000 000000000 17-Feb-2016 00000 00000 00 000.00 Completed
  • 5 buyers
Alvesco, Omnaris and Zetonna (Asthma Medication) 16-Dec-2015 Corporate Asset Purchase Completed
You’re viewing 5 of 13 exits. Get the full list »